NL300293I2 - Nieuwe derivaten van 3,3-difenylpropylaminen - Google Patents
Nieuwe derivaten van 3,3-difenylpropylaminenInfo
- Publication number
- NL300293I2 NL300293I2 NL300293C NL300293C NL300293I2 NL 300293 I2 NL300293 I2 NL 300293I2 NL 300293 C NL300293 C NL 300293C NL 300293 C NL300293 C NL 300293C NL 300293 I2 NL300293 I2 NL 300293I2
- Authority
- NL
- Netherlands
- Prior art keywords
- compounds
- diphenylpropylamines
- novel
- preparation
- methods
- Prior art date
Links
- KISZTEOELCMZPY-UHFFFAOYSA-N 3,3-diphenylpropylamine Chemical class C=1C=CC=CC=1C(CCN)C1=CC=CC=C1 KISZTEOELCMZPY-UHFFFAOYSA-N 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 229940079593 drug Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 abstract 1
- 206010046543 Urinary incontinence Diseases 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 208000013403 hyperactivity Diseases 0.000 abstract 1
- 208000002551 irritable bowel syndrome Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000003149 muscarinic antagonist Substances 0.000 abstract 1
- 229960005434 oxybutynin Drugs 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 210000002460 smooth muscle Anatomy 0.000 abstract 1
- 229960004045 tolterodine Drugs 0.000 abstract 1
- OOGJQPCLVADCPB-HXUWFJFHSA-N tolterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 OOGJQPCLVADCPB-HXUWFJFHSA-N 0.000 abstract 1
- BDIAUFOIMFAIPU-UHFFFAOYSA-N valepotriate Natural products CC(C)CC(=O)OC1C=C(C(=COC2OC(=O)CC(C)C)COC(C)=O)C2C11CO1 BDIAUFOIMFAIPU-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C219/26—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/48—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
- C07C217/62—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C219/26—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C219/28—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton having amino groups bound to acyclic carbon atoms of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
- C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/44—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
- C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/52—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C307/02—Monoamides of sulfuric acids or esters thereof, e.g. sulfamic acids
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Luminescent Compositions (AREA)
- Heat Sensitive Colour Forming Recording (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
- Saccharide Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Photoreceptors In Electrophotography (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98108608A EP0957073A1 (de) | 1998-05-12 | 1998-05-12 | 3,3-Diphenylpropylaminderivate |
| EP99924929A EP1077912B1 (de) | 1998-05-12 | 1999-05-11 | 3,3-diphenylpropylaminderivate |
| PCT/EP1999/003212 WO1999058478A1 (en) | 1998-05-12 | 1999-05-11 | Novel derivatives of 3,3-diphenylpropylamines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NL300293I1 NL300293I1 (nl) | 2007-11-01 |
| NL300293I2 true NL300293I2 (nl) | 2008-03-03 |
Family
ID=8231918
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL300293C NL300293I2 (nl) | 1998-05-12 | 2007-09-13 | Nieuwe derivaten van 3,3-difenylpropylaminen |
Country Status (32)
| Country | Link |
|---|---|
| US (6) | US6713464B1 (de) |
| EP (3) | EP0957073A1 (de) |
| JP (3) | JP3929702B2 (de) |
| KR (1) | KR100599004B1 (de) |
| CN (2) | CN1207268C (de) |
| AT (1) | ATE220056T1 (de) |
| AU (1) | AU748057B2 (de) |
| BR (1) | BRPI9910406B8 (de) |
| CA (1) | CA2328920C (de) |
| CY (1) | CY2007024I2 (de) |
| CZ (2) | CZ299721B6 (de) |
| DE (2) | DE122007000065I2 (de) |
| DK (1) | DK1077912T3 (de) |
| ES (1) | ES2181443T3 (de) |
| FR (1) | FR07C0050I2 (de) |
| GE (1) | GEP20084461B (de) |
| HK (2) | HK1046269B (de) |
| HU (2) | HU226490B1 (de) |
| IL (1) | IL139110A0 (de) |
| IS (1) | IS2044B (de) |
| LU (1) | LU91365I2 (de) |
| MX (1) | MXPA00011096A (de) |
| NL (1) | NL300293I2 (de) |
| NO (2) | NO326872B1 (de) |
| NZ (1) | NZ507487A (de) |
| PL (3) | PL218882B1 (de) |
| PT (1) | PT1077912E (de) |
| RU (1) | RU2199525C2 (de) |
| SK (1) | SK286052B6 (de) |
| TR (1) | TR200003319T2 (de) |
| WO (1) | WO1999058478A1 (de) |
| ZA (1) | ZA200005728B (de) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0957073A1 (de) | 1998-05-12 | 1999-11-17 | Schwarz Pharma Ag | 3,3-Diphenylpropylaminderivate |
| DE19955190A1 (de) * | 1999-11-16 | 2001-06-21 | Sanol Arznei Schwarz Gmbh | Stabile Salze neuartiger Derivate von 3,3-Diphenylpropylaminen |
| SE9904850D0 (sv) * | 1999-12-30 | 1999-12-30 | Pharmacia & Upjohn Ab | Novel process and intermediates |
| DE10028443C1 (de) * | 2000-06-14 | 2002-05-29 | Sanol Arznei Schwarz Gmbh | Verfahren zur Herstellung von 3,3-Diarylpropylaminen, (R,S)- und (R)-4-Phenyl-2-chromanon-6-carbonsäure sowie (R)-4-Phenyl-2-chromanon-carbonsäure-cinchonidinsalz und deren Verwendung zur Herstellung eines rechtsdrehenden Hydroxybenzylalkohols und von pharmazeutischen Zusammensetzungen |
| DE10033016A1 (de) * | 2000-07-07 | 2002-01-24 | Sanol Arznei Schwarz Gmbh | Verfahren zur Herstellung von 3,3-Diarylpropylaminen |
| EP1424079A1 (de) * | 2002-11-27 | 2004-06-02 | Boehringer Ingelheim International GmbH | Kombination eines beta-3-Rezeptoragonisten und eines Serotonin und/oder Norepinephrin-Wiederaufnahmeinhibitors |
| DE10315878B4 (de) * | 2003-04-08 | 2009-06-04 | Schwarz Pharma Ag | Vorrichtung zur transdermalen Verabreichung von Fesoterodin und Verwendung |
| DE10315917A1 (de) | 2003-04-08 | 2004-11-18 | Schwarz Pharma Ag | Hochreine Basen von 3,3-Diphenylpropylaminmonoestern |
| WO2004091597A2 (en) * | 2003-04-15 | 2004-10-28 | Pharmacia & Upjohn Company Llc | Method of treating irritable bowel syndrome (ibs) |
| EP1620389A1 (de) * | 2003-04-25 | 2006-02-01 | Pharmacia & Upjohn Company LLC | Halogen-substituierte 3,3-diphenylpropylamine (tolterodin) mit antimuscarinerger wirkung |
| ATE545627T1 (de) | 2003-05-23 | 2012-03-15 | Bridge Pharma Inc | Glattmuskelspasmolytika |
| WO2005012227A2 (en) * | 2003-08-05 | 2005-02-10 | Ranbaxy Laboratories Limited | Process for preparation of 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethyl-phenol, a metabolite of tolterodine |
| WO2007039918A1 (en) * | 2005-10-06 | 2007-04-12 | Natco Pharma Limited | Novel process for the preparation of tolterodine |
| KR20080076961A (ko) * | 2005-12-20 | 2008-08-20 | 화이자 프로덕츠 인크. | Ｐｄｅ５ 억제제 및 무스카린성 길항제를 포함하는ｌｕｔｓ의 치료를 위한 약제학적 조합물 |
| US8119667B2 (en) * | 2005-12-29 | 2012-02-21 | Schering-Plough Animal Health Corporation | Carbonates of fenicol antibiotics |
| US8067594B2 (en) * | 2006-05-24 | 2011-11-29 | Pfizer Inc. | Process for the production of benzopyran-2-ol derivatives |
| CN101454273B (zh) * | 2006-05-31 | 2013-08-21 | 施瓦茨制药有限公司 | 取代的羟甲基苯酚的合成方法 |
| EP1862449A1 (de) * | 2006-05-31 | 2007-12-05 | Schwarz Pharma Ltd. | Verkürzte Synthese von substituierten Hydroxymethylphenolen |
| IES20060424A2 (en) | 2006-06-08 | 2007-10-31 | Schwarz Pharma Ltd | Accelerated synthesis of (3-Diisopropylamino-1-phenylpropyl)-4-(hydroxymethyl)phenol and its phenolic monoesters |
| CA2648333C (en) * | 2006-06-09 | 2014-04-29 | Schwarz Pharma Ltd | Synthesis of phenolic esters of hydroxymethyl phenols |
| US7807715B2 (en) | 2006-06-09 | 2010-10-05 | Ucb Pharma Gmbh | Pharmaceutical compositions comprising fesoterodine |
| ES2370943T3 (es) * | 2006-06-09 | 2011-12-23 | Ucb Pharma Gmbh | Composiciones farmacéuticas estabilizadas que comprenden fesoterodina. |
| CA2647990C (en) * | 2006-06-12 | 2014-02-04 | Claus Meese | New chiral intermediate, process for producing the same and its use in the manufacture of tolterodine, fesoterodine, or the active metabolite thereof |
| IES20060435A2 (en) | 2006-06-12 | 2007-12-12 | Schwarz Pharma Ltd | Shortened synthesis using paraformaldehyde or trioxane |
| CZ298448B6 (cs) * | 2006-08-09 | 2007-10-03 | Zentiva, A. S. | Farmaceutická kompozice s obsahem tolterodinu |
| JP4859255B2 (ja) * | 2006-11-17 | 2012-01-25 | 旭化成ケミカルズ株式会社 | イソシアネートの製造方法 |
| TW200844080A (en) | 2007-01-11 | 2008-11-16 | Asahi Kasei Chemicals Corp | Process for producing isocyanate |
| WO2008144602A1 (en) * | 2007-05-18 | 2008-11-27 | Auspex Pharmaceuticals, Inc. | Deuterated zamifenacin derivatives |
| WO2009006413A1 (en) * | 2007-06-30 | 2009-01-08 | Auspex Pharmaceuticals, Inc. | Substituted pyrrolidines |
| US20090062385A1 (en) * | 2007-08-29 | 2009-03-05 | Protia, Llc | Deuterium-enriched fesoterodine |
| US20090062398A1 (en) * | 2007-08-29 | 2009-03-05 | Protia, Llc | Deuterium-enriched tolterodine |
| WO2009037569A2 (en) * | 2007-09-21 | 2009-03-26 | Actavis Group Ptc Ehf | An improved process for the preparation of fesoterodine |
| WO2009044278A1 (en) * | 2007-10-01 | 2009-04-09 | Actavis Group Ptc Ehf | Amorphous fesoterodine fumarate |
| WO2009058216A1 (en) * | 2007-11-01 | 2009-05-07 | Acucela, Inc. | Amine derivative compounds for treating ophthalmic diseases and disorders |
| US20110086103A1 (en) * | 2008-04-04 | 2011-04-14 | Actavis Group Ptc Ehf | Novel mandelate salt of fesoterodine |
| EP2275405B1 (de) | 2008-05-15 | 2019-04-24 | Asahi Kasei Kabushiki Kaisha | Verfahren zur herstellung von isocyanat unter einsatz von kohlensäurediarylestern |
| CN102026965B (zh) | 2008-05-15 | 2014-02-26 | 旭化成化学株式会社 | 异氰酸酯的制造方法 |
| US20110171274A1 (en) * | 2008-07-21 | 2011-07-14 | Actavis Group Ptc Ehf | Fesoterodine Substantially Free of Dehydroxy Impurity |
| JP5381086B2 (ja) * | 2008-10-06 | 2014-01-08 | 日本電気株式会社 | 通信システム及び通信制御方法 |
| PL2416761T3 (pl) | 2009-05-11 | 2015-07-31 | Ratiopharm Gmbh | Desfezoterodyna w postaci soli kwasu winowego |
| IT1394219B1 (it) | 2009-05-15 | 2012-06-01 | Chemi Spa | Metodo di preparazione di fesoterodina fumarato di elevata purezza. |
| IT1394217B1 (it) | 2009-05-15 | 2012-06-01 | Chemi Spa | Metodo di preparazione di fesoterodina e/o fesoterodina fumarato. |
| EP2281801B1 (de) | 2009-07-27 | 2014-01-08 | Crystal Pharma, S.A.U. | Verfahren zur Herstellung von 3,3-Diphenylpropylaminen |
| IT1396373B1 (it) | 2009-10-29 | 2012-11-19 | Dipharma Francis Srl | Procedimento per la preparazione di fesoterodina. |
| EP2316432A1 (de) | 2009-10-30 | 2011-05-04 | ratiopharm GmbH | Zusammensetzung enthaltend Fesoterodin und Ballaststoffe |
| US20110124903A1 (en) * | 2009-11-20 | 2011-05-26 | Actavis Group Ptc Ehf | Solid state forms of fesoterodine intermediates |
| IT1397521B1 (it) | 2009-12-21 | 2013-01-16 | Dipharma Francis Srl | Procedimento per la preparazione di fesoterodina con un basso contenuto di impurezze. |
| EP2364966A1 (de) | 2010-03-09 | 2011-09-14 | LEK Pharmaceuticals d.d. | Verfahren zur Herstellung von 3-(2-hydroxy-5-substituierten phenyl)-3-phenylpropylaminen, Zwischenprodukte zur Herstellung von Hydroxytolterodin |
| WO2011117884A1 (en) | 2010-03-22 | 2011-09-29 | Cadila Healthcare Limited | Stable pharmaceutical compositions comprising fesoterodine |
| ES2604705T3 (es) | 2010-03-31 | 2017-03-08 | Ono Pharmaceutical Co., Ltd. | Agente preventivo y/o remedio para el síndrome mano-pie |
| AU2011245499B2 (en) | 2010-04-30 | 2014-09-25 | Merck Sharp & Dohme Corp. | Novel beta 3 adrenergic receptor agonists |
| US20110282094A1 (en) | 2010-05-11 | 2011-11-17 | Intas Pharmaceuticals Limited | Process for preparation of phenolic monoesters of hydroxymethyl phenols |
| IT1401451B1 (it) | 2010-06-10 | 2013-07-26 | Chemi Spa | Nuovo processo di preparazione di 2-idrossi-4-fenil-3,4-diidro-2h-cromen-6-il-metanolo e (r)-2-[3-(diisopropilammino)-1-fenilpropil]-4-(idrossimetil)fenolo. |
| WO2011158257A1 (en) | 2010-06-18 | 2011-12-22 | Panacea Biotec Ltd | Preparation process of fesoterodine and intermediates |
| US9012678B2 (en) * | 2010-08-25 | 2015-04-21 | Cadila Healthcare Limited | Processes for the preparation of fesoterodine |
| US8492557B2 (en) * | 2010-09-16 | 2013-07-23 | Allergan, Inc. | Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol |
| IT1403094B1 (it) | 2010-12-09 | 2013-10-04 | Dipharma Francis Srl | Procedimento per la preparazione di fesoterodina o un suo sale |
| WO2012098560A2 (en) * | 2011-01-17 | 2012-07-26 | Msn Laboratories Limited | Process for the preparation of muscarinic receptor antagonist |
| TWI520732B (zh) | 2011-01-18 | 2016-02-11 | 輝瑞有限公司 | 固體分子分散液 |
| US9085509B2 (en) | 2011-04-07 | 2015-07-21 | Alembic Pharmaceuticals Limited | Process for preparing fesoterodine |
| EP2508173A1 (de) | 2011-04-08 | 2012-10-10 | LEK Pharmaceuticals d.d. | Stabile pharmazeutische Zusammensetzung mit Fesoterodin |
| EP2508175A1 (de) | 2011-04-08 | 2012-10-10 | LEK Pharmaceuticals d.d. | Pharmazeutische Zusammensetzung enthaltend Fesoterodin oder ein Salz oder ein Solvat davon |
| WO2013021343A1 (en) | 2011-08-05 | 2013-02-14 | Ranbaxy Laboratories Limited | Process for the optical resolution of () -3- (2 -benzyloxy- 5 - bromophenyl) - 3 - phenylpropionic |
| WO2013046135A1 (en) | 2011-09-26 | 2013-04-04 | Ranbaxy Laboratories Limited | Process for the preparation of fesoterodine or its salts |
| EP2800735B1 (de) | 2012-01-07 | 2016-03-30 | Alembic Pharmaceuticals Limited | Verfahren zur herstellung von fesoterodin |
| CN103304356B (zh) * | 2012-03-12 | 2016-01-20 | 北京乐威泰克医药技术有限公司 | 羟胺的合成方法 |
| WO2013113946A2 (en) | 2012-05-04 | 2013-08-08 | Crystal Pharma, S.A.U. | Process for the preparation of optically active 3,3-diphenylpropylamines |
| WO2013046194A2 (en) | 2012-05-18 | 2013-04-04 | Alembic Pharmaceuticals Limited | The novel reference markers for fesoterodine fumarate |
| ES2569201T3 (es) | 2012-06-14 | 2016-05-09 | Ratiopharm Gmbh | Sales de desfesoterodina |
| ITMI20121232A1 (it) * | 2012-07-16 | 2014-01-17 | Cambrex Profarmaco Milano Srl | Procedimento per la preparazione di 2-(3-n,n-diisopropilamino-1-fenilpropil)-4-idrossimetil-fenolo e suoi derivati |
| CZ2014400A3 (cs) | 2014-06-09 | 2015-12-16 | Zentiva, K.S. | Stabilizovaná formulace fesoterodinu |
| US9751828B2 (en) | 2014-07-30 | 2017-09-05 | Dipharma Francis S.R.L. | Antimuscarinic compound having a low content of impurities |
| TR201721437A2 (tr) | 2017-12-25 | 2019-07-22 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Fesoterodi̇ni̇n modi̇fi̇ye salim sağlayan formülasyonlari |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE766207C (de) | 1940-07-08 | 1952-12-22 | Ig Farbenindustrie Ag | Verfahren zur Herstellung von basischen Verbindungen der Diarylmethanreihe |
| DE925468C (de) | 1941-08-13 | 1955-03-21 | Hoechst Ag | Verfahren zur Herstellung von ª†, ª†-Diaryl-propyl-aminen |
| GB624117A (en) | 1946-12-07 | 1949-05-27 | Wellcome Found | Improvements in and relating to the preparation of substituted allylamines and propylamines |
| GB627139A (en) | 1947-05-28 | 1949-07-29 | Wellcome Found | Improvements in and relating to the preparation of quaternary ammonium salts of substituted propanolamines, allylamines and propylamines |
| BE497819A (de) | 1947-10-28 | |||
| US2567245A (en) | 1948-05-10 | 1951-09-11 | Schering Corp | Aryl-(2-pyridyl)-amino alkanes and their production |
| US2556636A (en) | 1948-06-23 | 1951-06-12 | Schering Corp | gamma-substituted propylamine type antihistamines |
| DE830193C (de) | 1948-11-09 | 1952-02-04 | Farbwerke Hoechst Vormals Meis | Verfahren zur Herstellung von basischen Verbindungen |
| CH287776A (de) | 1948-11-09 | 1952-12-15 | Michael Dr Erlenbach | Verfahren zur Herstellung einer basischen Verbindung. |
| GB685696A (en) | 1948-11-23 | 1953-01-07 | Schering Corp | Process for the manufacture of anti-histaminic compounds |
| NL74271C (de) | 1949-09-05 | |||
| US2676964A (en) | 1950-06-07 | 1954-04-27 | Schering Corp | 3-pyridyl propylamine antihistamine substances |
| US3261841A (en) | 1961-05-03 | 1966-07-19 | Sterling Drug Inc | N-substituted 1,5-iminocycloalkanes and -alkenes |
| US3216841A (en) * | 1962-04-30 | 1965-11-09 | Clevite Corp | Metal slip casting composition |
| DK111894A (de) | 1962-11-15 | |||
| GB1025041A (en) | 1964-02-21 | 1966-04-06 | Hoechst Ag | Process for the manufacture of diphenylalkylamines |
| GB1169945A (en) | 1966-08-25 | 1969-11-05 | Geistlich Soehne Ag | Pharmaceutical Compositions containing Diphenylalkyl-amine Derivatives |
| GB1169944A (en) | 1966-08-25 | 1969-11-05 | Geistlich Soehne Ag | Novel 3,3-Diphenylpropylamines and processes for the preparation thereof |
| HU200591B (en) | 1986-07-11 | 1990-07-28 | Chinoin Gyogyszer Es Vegyeszet | Process for producing new diphenyl propylamine derivatives and pharmaceutical compositions comprising such compounds |
| US5382600A (en) | 1988-01-22 | 1995-01-17 | Pharmacia Aktiebolag | 3,3-diphenylpropylamines and pharmaceutical compositions thereof |
| SE8800207D0 (sv) | 1988-01-22 | 1988-01-22 | Kabivitrum Ab | Nya aminer, deras anvendning och framstellning |
| US5693144A (en) * | 1990-03-19 | 1997-12-02 | 3D Systems, Inc. | Vibrationally enhanced stereolithographic recoating |
| ATE185694T1 (de) | 1992-05-13 | 1999-11-15 | Alza Corp | Oxybutynin zur transdermalen verabreichung |
| SE9203318D0 (sv) * | 1992-11-06 | 1992-11-06 | Kabi Pharmacia Ab | Novel 3,3-diphenylpropylamines, their use and preparation |
| US6071970A (en) | 1993-02-08 | 2000-06-06 | Nps Pharmaceuticals, Inc. | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases |
| AU7994694A (en) | 1994-10-21 | 1996-05-15 | Leiras Oy | Controlled release oral delivery system containing oxybutynin |
| WO1998003067A1 (en) | 1996-07-19 | 1998-01-29 | Gunnar Aberg | S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders |
| WO1998025590A2 (de) | 1996-12-12 | 1998-06-18 | Dds Drug Delivery Service Gesellschaft Zur Förderung Der Forschung In Pharmazeutischer Technologie Und Biopharmazie Mbh | Zubereitung in form eines wahlweise wirkstoffhaltigen matrixmaterial-hilfsstoff compounds |
| KR20000057548A (ko) | 1996-12-13 | 2000-09-25 | 알프레드 엘. 미첼슨 | 광학적 전송물질 및 결합재 |
| SE9701144D0 (sv) | 1997-03-27 | 1997-03-27 | Pharmacia & Upjohn Ab | Novel compounds, their use and preparation |
| EP0872233A1 (de) | 1997-04-14 | 1998-10-21 | Janssen Pharmaceutica N.V. | Antiretrovirale Arzneimittel mit verbesserter Bioverfügbarkeit |
| WO1998056359A2 (de) | 1997-06-13 | 1998-12-17 | Roland Bodmeier | Zusammensetzungen, die die wirkstofffreisetzung verzögern |
| EP0957073A1 (de) | 1998-05-12 | 1999-11-17 | Schwarz Pharma Ag | 3,3-Diphenylpropylaminderivate |
| SE9802864D0 (sv) | 1998-08-27 | 1998-08-27 | Pharmacia & Upjohn Ab | Transdermally administered tolterodine as antimuscarinic agent for the treatment of overactive bladder |
| SE9803871D0 (sv) | 1998-11-11 | 1998-11-11 | Pharmacia & Upjohn Ab | Therapeutic method and formulation |
| CA2311755C (en) | 1998-08-27 | 2010-03-23 | Pharmacia & Upjohn Ab | Therapeutic formulation for administering tolterodine with controlled release |
| DE19922662C1 (de) | 1999-05-18 | 2000-12-28 | Sanol Arznei Schwarz Gmbh | Transdermales therapeutisches System (TTS) Tolterodin enthaltend |
| ES2245320T3 (es) | 1999-11-11 | 2006-01-01 | Pfizer Health Ab | Formulacion farmaceutica que contiene tolterodina y su uso. |
| DE19955190A1 (de) | 1999-11-16 | 2001-06-21 | Sanol Arznei Schwarz Gmbh | Stabile Salze neuartiger Derivate von 3,3-Diphenylpropylaminen |
| US6566537B2 (en) | 1999-12-30 | 2003-05-20 | Pharmacia Ab | Process and intermediates |
| SE9904850D0 (sv) | 1999-12-30 | 1999-12-30 | Pharmacia & Upjohn Ab | Novel process and intermediates |
| DE10028443C1 (de) | 2000-06-14 | 2002-05-29 | Sanol Arznei Schwarz Gmbh | Verfahren zur Herstellung von 3,3-Diarylpropylaminen, (R,S)- und (R)-4-Phenyl-2-chromanon-6-carbonsäure sowie (R)-4-Phenyl-2-chromanon-carbonsäure-cinchonidinsalz und deren Verwendung zur Herstellung eines rechtsdrehenden Hydroxybenzylalkohols und von pharmazeutischen Zusammensetzungen |
| DE10033016A1 (de) | 2000-07-07 | 2002-01-24 | Sanol Arznei Schwarz Gmbh | Verfahren zur Herstellung von 3,3-Diarylpropylaminen |
| US20030086972A1 (en) | 2000-08-09 | 2003-05-08 | Appel Leah E. | Hydrogel-driven drug dosage form |
| AR033711A1 (es) | 2001-05-09 | 2004-01-07 | Novartis Ag | Composiciones farmaceuticas |
| US20030027856A1 (en) | 2001-06-29 | 2003-02-06 | Aberg A.K. Gunnar | Tolterodine metabolites |
| GB0117619D0 (en) | 2001-07-19 | 2001-09-12 | Phoqus Ltd | Pharmaceutical dosage form |
| EP1423700A2 (de) | 2001-09-04 | 2004-06-02 | Pfizer Limited | Affinitätsassay für den humanen erg kaliumkanal |
| JP2005506323A (ja) | 2001-09-05 | 2005-03-03 | ベクトゥラ・リミテッド | 経口送達用機能性散剤 |
| WO2003026564A2 (en) | 2001-09-27 | 2003-04-03 | Pharmacia Ab | Pharmaceutical compositions for the treatment of urinary disorders |
| JP3981357B2 (ja) | 2001-10-26 | 2007-09-26 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | 第４級アンモニウム化合物および抗ムスカリン剤としてのそれらの使用 |
| JP2005511582A (ja) | 2001-11-05 | 2005-04-28 | ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー | 抗ムスカリン・エアゾール |
| US20030152624A1 (en) | 2001-12-20 | 2003-08-14 | Aldrich Dale S. | Controlled release dosage form having improved drug release properties |
| KR100540035B1 (ko) | 2002-02-01 | 2005-12-29 | 주식회사 태평양 | 다단계 경구 약물 방출 제어 시스템 |
| DE10224107A1 (de) | 2002-05-29 | 2003-12-11 | Gruenenthal Gmbh | Kombination ausgewählter Opioide mit anderen Wirkstoffen zur Therapie der Harninkontinenz |
| CN1674877A (zh) | 2002-06-07 | 2005-09-28 | 兰贝克赛实验室有限公司 | 控释的多单位药物释放系统 |
| ITMI20021329A1 (it) | 2002-06-14 | 2003-12-15 | Recordati Chem Pharm | Nuove ossialchilammine sostituite |
| WO2004019892A2 (en) | 2002-08-30 | 2004-03-11 | Watson Pharmaceuticals, Inc. | Drug delivery system for treating urinary incontinence |
| TW200408955A (en) | 2002-09-30 | 2004-06-01 | Advent Networks Inc | Implementing request/reply programming semantics using publish/subscribe middleware |
| DE10315917A1 (de) * | 2003-04-08 | 2004-11-18 | Schwarz Pharma Ag | Hochreine Basen von 3,3-Diphenylpropylaminmonoestern |
| DE10315878B4 (de) * | 2003-04-08 | 2009-06-04 | Schwarz Pharma Ag | Vorrichtung zur transdermalen Verabreichung von Fesoterodin und Verwendung |
| EP1620389A1 (de) | 2003-04-25 | 2006-02-01 | Pharmacia & Upjohn Company LLC | Halogen-substituierte 3,3-diphenylpropylamine (tolterodin) mit antimuscarinerger wirkung |
-
1998
- 1998-05-12 EP EP98108608A patent/EP0957073A1/de not_active Withdrawn
-
1999
- 1999-05-11 RU RU2000125813/04A patent/RU2199525C2/ru active Protection Beyond IP Right Term
- 1999-05-11 CN CNB998060380A patent/CN1207268C/zh not_active Expired - Lifetime
- 1999-05-11 HU HU0100779A patent/HU226490B1/hu active Protection Beyond IP Right Term
- 1999-05-11 JP JP2000548284A patent/JP3929702B2/ja not_active Expired - Lifetime
- 1999-05-11 DE DE122007000065C patent/DE122007000065I2/de active Active
- 1999-05-11 HU HU0600760A patent/HU230434B1/hu unknown
- 1999-05-11 CA CA002328920A patent/CA2328920C/en not_active Expired - Lifetime
- 1999-05-11 MX MXPA00011096A patent/MXPA00011096A/es unknown
- 1999-05-11 IL IL13911099A patent/IL139110A0/xx active Protection Beyond IP Right Term
- 1999-05-11 NZ NZ507487A patent/NZ507487A/xx not_active IP Right Cessation
- 1999-05-11 PT PT99924929T patent/PT1077912E/pt unknown
- 1999-05-11 PL PL380733A patent/PL218882B1/pl unknown
- 1999-05-11 PL PL99347823A patent/PL195581B1/pl unknown
- 1999-05-11 KR KR1020007012653A patent/KR100599004B1/ko active IP Right Grant
- 1999-05-11 CN CNB2005100702999A patent/CN100491336C/zh not_active Expired - Lifetime
- 1999-05-11 EP EP99924929A patent/EP1077912B1/de not_active Expired - Lifetime
- 1999-05-11 DE DE69902037T patent/DE69902037T2/de not_active Expired - Lifetime
- 1999-05-11 SK SK1547-2000A patent/SK286052B6/sk not_active IP Right Cessation
- 1999-05-11 EP EP02013481A patent/EP1254890A1/de not_active Withdrawn
- 1999-05-11 US US09/700,094 patent/US6713464B1/en not_active Expired - Lifetime
- 1999-05-11 ES ES99924929T patent/ES2181443T3/es not_active Expired - Lifetime
- 1999-05-11 CZ CZ20060029A patent/CZ299721B6/cs not_active IP Right Cessation
- 1999-05-11 TR TR2000/03319T patent/TR200003319T2/xx unknown
- 1999-05-11 WO PCT/EP1999/003212 patent/WO1999058478A1/en active IP Right Grant
- 1999-05-11 DK DK99924929T patent/DK1077912T3/da active
- 1999-05-11 PL PL380081A patent/PL202489B1/pl unknown
- 1999-05-11 BR BRPI9910406A patent/BRPI9910406B8/pt not_active IP Right Cessation
- 1999-05-11 CZ CZ20003774A patent/CZ296605B6/cs not_active IP Right Cessation
- 1999-05-11 AT AT99924929T patent/ATE220056T1/de active
- 1999-05-11 AU AU41412/99A patent/AU748057B2/en not_active Expired
-
2000
- 2000-10-17 ZA ZA200005728A patent/ZA200005728B/xx unknown
- 2000-10-17 IS IS5670A patent/IS2044B/is unknown
- 2000-11-10 NO NO20005669A patent/NO326872B1/no not_active IP Right Cessation
-
2002
- 2002-10-30 HK HK02107859.3A patent/HK1046269B/zh not_active IP Right Cessation
-
2004
- 2004-01-27 US US10/766,263 patent/US7230030B2/en not_active Expired - Lifetime
-
2005
- 2005-08-10 US US11/201,756 patent/US7384980B2/en not_active Expired - Fee Related
-
2006
- 2006-04-11 HK HK06104367.1A patent/HK1084099A1/xx not_active IP Right Cessation
- 2006-10-18 JP JP2006283861A patent/JP4658895B2/ja not_active Expired - Lifetime
-
2007
- 2007-02-20 JP JP2007039857A patent/JP4833884B2/ja not_active Expired - Lifetime
- 2007-09-10 GE GEAP200710260A patent/GEP20084461B/en unknown
- 2007-09-13 NL NL300293C patent/NL300293I2/nl unknown
- 2007-09-14 LU LU91365C patent/LU91365I2/fr unknown
- 2007-10-04 FR FR07C0050C patent/FR07C0050I2/fr active Active
- 2007-10-15 CY CY2007024C patent/CY2007024I2/el unknown
-
2008
- 2008-04-17 US US12/105,016 patent/US7855230B2/en not_active Expired - Fee Related
-
2009
- 2009-07-17 NO NO2009015C patent/NO2009015I2/no unknown
-
2010
- 2010-06-14 US US12/814,982 patent/US7985772B2/en not_active Expired - Fee Related
-
2011
- 2011-06-15 US US13/161,049 patent/US8338478B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL300293I2 (nl) | Nieuwe derivaten van 3,3-difenylpropylaminen | |
| GR3036286T3 (en) | 9-deoxotaxane compounds | |
| MX9302214A (es) | Derivados de taxol y proceso para su preparacion | |
| ATE113604T1 (de) | Mometason-furoate-monohydrat, verfahren zu seiner herstellung und das enthaltende pharmazeutische zusammensetzungen. | |
| BR9707064A (pt) | Novos derivados 19-nor-pregneno | |
| PL298845A1 (en) | Arylecetamides, method of obtaining them as well as pharmaceutical preparation and method of obtaining same | |
| HK1155146A1 (zh) | 作為藥物活性劑的茚衍生物 | |
| EE200000014A (et) | (+)-nortsisapriidaluse valmistamismeetod, (+)-nortsisapriid, selle farmatseutiliselt vastuvõetav happe liitsool ja nende kasutamine, farmatseutiline kompositsioon ja selle valmistamismeetod ning vaheühend | |
| ATE247645T1 (de) | Neue piperazinylalkylthiopyrimidine derivate, diese enthaltende pharmazeutische zusammenstellungen und verfahren zu deren herstellung | |
| BR9808042A (pt) | Composto, composição farmacêutica, e, processo para preparação de compostos. | |
| IL163608A (en) | Sulfonanilides are conserved in their amino / amino acids and derivatives, their process, their pharmaceutical preparations, and their conjugated antibodies and their use in the preparation of drugs for the treatment of culture disorders | |
| WO1999058490A3 (en) | Novel aryl-hydro naphthalenal kanamines | |
| DZ3096A1 (fr) | Procédé pour la préparation de dérivés de pyrazoloÄ4,3-DÜpyrimidine-7-one-3-pyridylsulfonyle, et intermédiaires utilisés. | |
| DE69904661D1 (de) | Zinc-Molybdän-Dithiocarbamatderivate, Verfahren zu deren Herstellung und diese enthaltende Schmiermittelzusammensetzung | |
| EP1414457A4 (de) | Chirales dinapsolin | |
| NO20001140L (no) | Fremgangsmõte ved fremstilling av epoksid intermediater | |
| TW200509889A (en) | Aniline derivatives | |
| GB9926301D0 (en) | Novel compounds |